An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment
EndocrinologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Journal of pediatric endocrinology & metabolism : JPEM
- Publicado em
- 3 fev 2023
- Citações
- 45
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment
Zvi Zadik, Nataliya Zelinska, Violeta Iotova, Yulia Skorodok, Oleg Malievsky, Nelly Mauras, Srinivas Rao Valluri, Aleksandra Pastrak, Ron Rosenfeld
Descritores MeSH
- Dwarfism, Pituitary
- Human Growth Hormone
- Growth Disorders
- Body Height
- Insulin-Like Growth Factor I
- Growth Hormone
- Humans
- Child
Veja também
Estudos relacionados
- Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH
- Trends In Reported Outcomes for Growth Hormone Therapy In Children With Growth Hormone Deficiency
- Effect of Growth Hormone Therapy on Pubertal Timing: Systematic Review and Meta-Analysis
- Sex steroid priming for growth hormone stimulation testing in children and adolescents with short stature: A systematic review